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Abstract Mouse embryonic stem (ES) cells homozygous for
disruption of the MSK1 gene had no detectable MSK1 activity.
However, their activators (extracellular signal related kinase
(ERK)1/ERK2) were stimulated normally in mitogen- and stress-
activated protein kinase (MSK)13/3 and wild type cells in
response to tetradecanoylphorbol acetate (TPA) and epidermal
growth factor (EGF). TPA and EGF induced the phosphoryla-
tion of cyclic AMP-responsive element binding protein (CREB)
at Ser-133 and ATF1 at Ser-63 in wild type cells and this
was abolished by inhibition of the mitogen-activated protein
kinase cascade. In contrast, the TPA- and EGF-induced
phosphorylation of CREB/ATF1 was barely detectable in
MSK13/3 cells. However, basal and forskolin-induced phos-
phorylation was similar, indicating that the MSK1 ‘knockout’
did not prevent CREB phosphorylation by cyclic AMP-
dependent protein kinase. Thus MSK1 is required for CREB
and ATF1 phosphorylation after mitogenic stimulation of ES
cells. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cyclic AMP-responsive element binding protein (CREB) is
the prototypic member of a family of transcription factors
that regulate transcription by binding to cyclic AMP-respon-
sive elements (CREs) in gene promoters. CREB family mem-
bers have been implicated in the regulation of many processes,
including cell proliferation, di¡erentiation, metabolism and
neuronal and immune responses [1,2]. Partial mouse ‘knock-
outs’ for CREB have suggested a role for this protein in
memory [3], while the complete CREB ‘knockout’ leads to
perinatal lethality as well as defects in T cell development [4].
The transactivation potential of CREB depends on phos-
phorylation of a serine residue in the kinase inducible domain
(Ser-133 for CREB, Ser-63 for the closely related ATF1).
These residues are phosphorylated by cyclic AMP (cAMP)-
dependent protein kinase (PKA) in response to agonists that
elevate intracellular cAMP. The same sites on CREB and
ATF1 also become phosphorylated in response to growth
factors and cellular stresses, but via the classical mitogen-ac-
tivated protein kinase (MAPK) cascade [5,6] and the stress-
activated protein kinase 2 (SAPK2, also called p38) pathway
[7], respectively. However, while the phosphorylation of
CREB is required for the full induction of many CRE-depen-
dent genes, it is often insu⁄cient to induce transcription per
se, the activation of additional transcription factors being re-
quired.
The phosphorylation of Ser-133 (CREB) or Ser-63 (ATF1)
is not catalysed by MAPK family members directly but by
other protein kinases that they activate. Two protein kinases
that are activated by extracellular signal related kinase
(ERK)1 and ERK2, the MAPK family members of the clas-
sical pathway, are MAPK-activated protein kinase-1 (MAP-
KAP-K1, also called RSK) and mitogen- and stress-activated
protein kinase (MSK). Both protein kinases phosphorylate
CREB at Ser-133 in vitro, and mitogen-induced phosphoryla-
tion of this site is prevented by Ro 318220, a potent inhibitor
of MAPKAP-K1 and MSK isoforms, consistent with the in-
volvement of one or both enzymes [8]. However, there is con-
troversy as to whether MAPKAP-K1 or MSK1 mediate the
phosphorylation of CREB at Ser-133 in vivo. Several lines of
evidence initially suggested that the phosphorylation of CREB
at Ser-133 was catalysed by the MAPKAP-K1b (RSK2) iso-
form. For example, MAPKAP-K1b was reported to be the
major CREB phosphorylating activity in extracts prepared
from NGF-stimulated rat phaeochromocytoma 12 cells and
to phosphorylate CREB more e⁄ciently in vitro than the
MAPKAP-K1a (RSK1) isoform [7,9]. In addition, ¢broblast
cell lines derived from human patients with Co⁄n^Lowry
syndrome, which carry inactivating point mutations in the
MAPKAP-K1b gene, were reported to be unable to phos-
phorylate CREB after stimulation with EGF [10]. More re-
cently, however, IGF1 was found to induce a normal phos-
phorylation of CREB at Ser-133 in immortalised ¢broblasts
isolated from mouse ‘knockouts’ of the MAPKAP-K1b gene
[11] and others found that MAPKAP-K1b did not phosphor-
ylate CREB any more e⁄ciently than MAPKAP-K1a in vitro
[8].
There are two isoforms of MSK, termed MSK1 and MSK2,
which share 75% amino acid sequence identity [8,12,13].
MSK1 was found to phosphorylate CREB in vitro with a
far lower Km value than MAPKAP-K1a or MAPKAP-K1b
and to be localised to nuclei in both unstimulated and stimu-
lated cells. This raises the possibility that MSK1 rather than
MAPKAP-K1 mediates the mitogen-induced phosphorylation
of CREB at Ser-133. In order to determine if MSK1 is a
mitogen-induced CREB kinase in vivo, we have developed
embryonic stem (ES) cell lines with targeted disruption of
the MSK1 gene locus. These cells do not express MSK1 ac-
tivity and, in this paper, we use them to study the e¡ect of
mitogens on the phosphorylation of CREB and ATF1.
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2. Materials and methods
2.1. Materials
Peptides were synthesised by Dr G. Blomberg (University of Bris-
tol, UK). Peptide antibodies raised in sheep against residues 26^44
(LTVKHELRTANLTGHAEKV), 384^402 (FKRNAAVIDPLQF-
HMGVER) of human MSK1 (which do not recognise MSK2) and
712^734 (RNQSPVLEPVGRSTLAQRRGIKK) of human MAP-
KAP-K1b have been described previously [8,19]. The MAPKAP-K1
antibody recognises both MAPKAP-K1a (RSK1) and MAPKAP-
K1b (RSK2). Isoform-speci¢c antibodies for MAPKAP K1a, MAP-
KAP-K1b and MAPKAP-K1c (RSK3) were Santa Cruz products
obtained from Autogen Bioclear (Calne, UK). A phospho-speci¢c
antibody, raised against the peptide KRREILSRRP*SYRK (where
* denotes a phosphorylated residue), which recognises CREB phos-
phorylated at Ser-133 and ATF1 phosphorylated at Ser-63, was pur-
chased from UBI (Lake Placid, USA), and an antibody which recog-
nises an epitope near the carboxy terminus of CREB and ATF1 was
from Santa Cruz (sc186). A phospho-speci¢c antibody that recognises
ERK1 and ERK2 phosphorylated at their Thr^Glu^Tyr motifs and
another antibody that recognises phosphorylated and dephosphory-
lated ERK1/ERK2 equally well were purchased from New England
Biolabs (Hitchin, UK). Antibodies that recognise GSK3K phosphor-
ylated on Ser-21 were raised in sheep against RARTSS*FAEPG [17].
Mouse EGF and microcystin-LR were purchased from Life Technol-
ogies (Paisley, UK) and tetradecanoylphorbol acetate (TPA) and for-
skolin from Sigma (Poole, UK).
2.2. Cloning of the MSK1 genomic locus
A 129Sv mouse BAC library (Incyte Genomics, MO, USA) was
screened using the open reading frame from a human MSK1 cDNA
[8], to obtain a clone containing the mouse MSK1 gene. EcoRI and
HindIII restriction fragments that hybridised to the human probe,
were subcloned into pBluescript and sequenced. This allowed the
identi¢cation of several MSK1 exon sequences, including the exon
encoding the start of the open reading frame. The area around this
region was mapped further and sequenced by subcloning overlapping
fragments from the BAC clone.
A targeting vector was constructed to delete from the MSK1 start
codon to the end of the ¢rst coding exon and insert transcription
termination sequences. The ¢rst arm of homology was generated by
PCR, during which NotI and BamHI sites were introduced at the 5P
and 3P ends, respectively. The arm was sequenced to ensure that there
were no PCR-generated mutations. The second arm of homology was
generated by subcloning the 4.8 kb XbaI fragment 3P to the deletion.
A thymidine kinase (TK) promoter-neo-pA cassette was inserted for
positive selection, and a TK cassette included for negative selection.
The vector was linearised at the NotI site before use.
2.3. ES cell targeting
Mouse ES cells were grown in DMEM (high glucose) supplemented
with 15% foetal bovine serum, 0.1 mM non-essential amino acids,
antibiotics (50 units/ml penicillin G, 50 Wg/ml streptomycin), 2 mM
L-glutamine, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol and
1000 U/ml leukaemia inhibitory factor (LIF). ES cells were main-
tained on a feeder layer of primary embryonic ¢broblasts before
and during the initial selections, which had been derived from trans-
genic mice homozygous for an inserted neo gene. Targetting of the
MSK1 gene to obtain ES cells heterozygous for the disruption was
performed using standard procedures [20]. Targeted cell lines were
identi¢ed by PCR using an antisense primer in the neo gene (P2,
ACTGCTCGACATTGGGTGGAAACATTCCAG) and a primer
outside the targeting vector (P1, CTTCCCGTCAGCCTCATGGGA-
TTCGACAAG). A wild type (WT) control was also used that in-
cluded a primer in the region to be deleted (P3, CTTCCCGT-
CAGCCTCATGGGATTCGACAAG). Targeted cell lines were con-
¢rmed by Southern analysis using a probe outside the 3P arm of the
vector (Fig. 1A).
Cell lines homozygous for the disruption were obtained by culturing
the cells in high concentrations of G418, which selected for gene
conversion. For this and subsequent assays, cells were grown on ge-
latinised tissue culture plastic in knockout DMEM supplemented with
10% ES replacement serum (Life Technologies) with the non-essential
amino acids, antibiotics, L-glutamine, 2-mercaptoethanol and LIF as
described above. Cells were selected in 4 mg/ml G418 for 15 days,
after which surviving colonies were isolated and expanded in the ab-
sence of G418. Cell lines were analysed by PCR and Southern blotting
to identify homozygous cell lines. When cells were to be serum-starved
they were incubated for 4^5 h in knockout DMEM (Gibco) supple-
mented with non-essential amino acids, antibiotics, L-glutamine and
0.1 mM 2-mercaptoethanol.
2.4. Cell stimulations
Cells were cultured to con£uence on gelatinised tissue culture plas-
tic, then incubated for 5 h in serum free medium. The cells were then
incubated with either no agonist (unstimulated), TPA (400 ng/ml),
EGF (100 ng/ml) or forskolin (20 mM)+isobutylmethyl xanthine
(IBMX, 10 mM). The cells were lysed in ice cold 50 mM Tris^HCl
pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 1 mM
sodium orthovanadate, 50 mM sodium £uoride, 5 mM sodium pyro-
phosphate, 0.27 M sucrose, 1 WM microcystin-LR, 0.1% (v/v) 2-mer-
captoethanol and complete proteinase inhibitor cocktail (Roche, East
Sussex, UK, one tablet per 50 ml). For immunoblotting of CREB,
Fig. 1. Generation of MSK13/3 ES cells. A: A targeting vector
was made to delete part of the ¢rst coding exon of the MSK1 gene.
The 5P untranslated region (grey box) was unchanged while the start
of the coding region from the ATG (black box) was deleted and re-
placed with a neomycin selection cassette and polyadenylation se-
quences. Also shown are the positions of the probe to screen for
the correct incorporation of the 3P end targeting vector by BamHI
digestion (horizontal bar), and PCR primers (P1, P2 and P3) to
screen for the 5P end. B: Genomic DNA from WT, MSK1+/3 and
MSK13/3 cells was digested with BamHI, run on an 0.8% agarose
gel and Southern-blotted using the 3P probe. 13 kb bands indicate a
WT locus and 7.8 kb bands a targeted locus. C: PCR analysis in
WT, MSK1+/3 and MSK13/3 cells using P1 and P2 (to demon-
strate the presence of a WT allele) or P1 and P3 (to show a tar-
geted allele). D: 20 Wg of lysate protein from WT, MSK1+/3 and
MSK13/3 cells was electrophoresed on a 10% SDS/polyacrylamide
gel and immuno-blotted using an antibody raised against the whole
MSK1 protein. The position of MSK1 is indicated by an arrow.
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cells were grown to con£uence on 6 cm gelatinised plates, serum-
starved, then stimulated and lysed in 0.5 ml boiling 50% (v/v) lysis
bu¡er, containing 1% (w/v) SDS and 5% (v/v) glycerol and heated for
10 min at 95‡C.
2.5. Other procedures
Immunoprecipitation and assay of MSK1 and MAPKAP-K1 was
carried out as described previously [16]. MAPKAP-K1 activity was
assayed with CROSSTIDE (GRPRTSSFAEG) as substrate and
MSK1 using glutathione-S-transferase^CREB fusion. One unit of
protein kinase activity was de¢ned as that amount of enzyme, which
phosphorylates 1 nmol of substrate in 1 min. Immunoblotting of cell
lysates was performed as described [16].
3. Results
3.1. Generation of MSK1 knockout cells
The disruption of the MSK1 gene was performed as de-
scribed under Section 2. Following transfection of the target-
ing vector, 386 ES cell colonies were screened for homologous
recombination. Of these, 12 were found to be heterozygous
for the disruption of the MSK1 gene. One of these was further
selected using high concentrations of G418 to obtain cell lines
homozygous for the disruption by gene conversion; from
24 colonies screened, three homozygous cell lines were ob-
tained. The genotype of these cell lines was con¢rmed by
PCR and Southern analysis (Fig. 1A^C). Due to the low level
of MSK1 in WT ES cells compared to many transformed cell
lines, antibodies against the MSK1 protein do not detect a
single band in immunoblotting experiments. However, a band
was detected at the correct molecular mass for MSK1 in
MSK1+/3 and WT cells which was absent in the MSK13/
3 cells (Fig. 1D). MSK1 was also immunoprecipitated using
two di¡erent anti-peptide antibodies (see Section 2), and the
immunoprecipitates examined by immunoblotting using the
MSK1 antibody raised against the whole protein. In each
case a single band was obtained in lysates from WT cells,
which was absent in the lysates from the MSK13/3 cells
(data not shown).
The MSK13/3 and MSK1+/3 cell lines had similar
growth rates and morphology to the WT cells, and were
also able to undergo in vitro di¡erentiation via embryoid
bodies into erythrocytes and macrophages. Immunoblotting
for ERK1/ERK2 (see later) and MAPKAP-K1 isoforms
(data not shown) revealed that these other components of
the MAPK cascade were present at similar levels in WT and
MSK13/3 cells.
3.2. TPA and EGF activate MSK1 and MAPKAP-K1 in ES
cells via the classical MAPK cascade
Stimulation of WT ES cells with either TPA or EGF re-
sulted in the activation of MSK1 and MAPKAP-K1a/b (Fig.
2A). The activation of both enzymes was blocked by PD
184352, a speci¢c inhibitor of the classical MAPK cascade
[14]. Consistent with these ¢ndings, TPA and EGF also acti-
Fig. 2. E¡ect of PD 184352 on TPA- and EGF-induced activation
of MAPKAP-K1, MSK1 and ERK1/ERK2 in WT ES cells. Cells
were serum-starved for 4 h, PD 184352 (PD, 10 WM) being added
where indicated 1 h prior to stimulation. The cells were then either
left unstimulated or stimulated with TPA (400 ng/ml, 10 min) or
EGF (100 ng/ml, 5 min). A: MAPKAP-K1a and MAPKAP-K1b
were coimmunoprecipitated from the lysates and assayed as de-
scribed in Section 2. Error bars represent S.E.M. of six points.
B: MSK1 was immunoprecipitated from the lysates and assayed as
described in Section 2. Error bars represent S.E.M. of six points.
C: An aliquot of each lysate (20Wg protein) was electrophoresed on
a 10% SDS polyacrylamide gel, transferred to nitrocellulose and im-
munoblotted using antibodies that recognise phospho-ERK1 and
ERK2 or dephospho plus phospho-ERK1 and ERK2 (total-ERK).
Fig. 3. Activation of MSK1 and ERK in MSK13/3 cells.
MSK3/3 (grey bars) and WT (black bars). ES cells were serum-
starved for 4 h and then stimulated with TPA (400 ng/ml) or EGF
(100 ng/ml) for the times indicated. A: MSK1 was immunoprecipi-
tated from the lysates with an antibody raised against amino acids
712^734 of human MSK1 from WT (grey bars) and MSK13/3
(black bars) cell lysates and assayed. Details are given under Section
2. Error bars represent S.E.M. of four points. B and C: Aliquots of
the cell lysates (20 Wg of protein) from TPA- (B) and EGF- (C)
stimulated cells were electrophoresed on 10% SDS^polyacrylamide
gels and immunoblotted using the antibodies described in Fig. 2.
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vated the MAPK family members ERK1 and ERK2 mea-
sured in the same lysates, and the phosphorylation of these
enzymes was also blocked by preincubation with PD 184352
(Fig. 2B). Together, these results demonstrate that TPA and
EGF activate MAPKAP-K1 and MSK1 via the classical
MAPK cascade.
3.3. MSK1 activity is abolished in MSK13/3 cells but ERKs,
MAPKAP-K1 and GSK3 activities are una¡ected
The activation of MSK1, ERK1/ERK2 and MAPKAP-K1
was compared in MSK13/3 and WT ES cells. The TPA-
induced and EGF-induced activation of MSK1 in WT cells
peaked after 10 and 5 min stimulation, respectively, but
MSK1 activity was not signi¢cantly above background at
any time point in the MSK13/3 cells (Fig. 3A). In contrast
TPA (Fig. 3B) and EGF (Fig. 3C) both induced ERK1 and
ERK2 phosphorylation, similarly in the MSK13/3 and WT
cells. Consistent with this ¢nding, all three isoforms of MAP-
KAP-K1 were activated in the same lysates (Fig. 4A^C). The
kinetics of activation and inactivation of MAPKAP-K1 in the
MSK13/3 and WT cells were similar to those observed for
MSK1 in WT cells.
The protein kinase GSK3 is inactivated by phosphorylation
of a serine residue (Ser-21 in GSK3K and Ser-9 in GSK3L).
This can be catalysed by PKB in response to agonists that
activate PI 3-kinase [15]) or by MAPKAP-K1 in response to
agonists that activate the classical MAPK cascade [16,17]. In
WT ES cells, GSK3K was partially phosphorylated at Ser-21
in unstimulated cells and this was prevented by preincubation
with LY 294002, an inhibitor of PI 3-kinase, indicating that
phosphorylation was catalysed by PKB. TPA and EGF both
stimulated the phosphorylation of Ser-21, even in the presence
of LY 294002, and this was blocked by the MAPK cascade
inhibitor PD 184352. Similar results were obtained in WT and
MSK3/3 cells (Fig. 4D).
3.4. Phosphorylation of CREB and ATF1 in WT and MSK13/
3 cells
The phosphorylation of CREB and ATF1, at Ser-133 and
Ser-63 respectively, was stimulated by TPA and EGF with
similar kinetics to the activation of MSK1 and MAPKAP-
Fig. 4. Activation of MAPKAP K1 isoforms and inhibition of
GSK3K by TPA and EGF in MSK13/3 and WT ES cells.
MSK13/3 (grey bars) and WT (black bars) ES cells were serum-
starved for 4 h and then left unstimulated or stimulated with TPA
(400 ng/ml) or EGF (100 ng/ml) for the times indicated. MAPKAP-
K1a (A), MAPKAP-K1b (B), and MAPKAP-K1c (C) were immu-
noprecipitated individually using isoform-speci¢c antibodies and as-
sayed as described in Section 2. Error bars represent the S.E.M. of
four points. D: Cells were serum-starved in the presence of LY
294002 (LY, 100 WM) or PD 184352 (PD, 10 WM) where indicated
and then left unstimulated, or stimulated with TPA (400 ng/ml,
10 min) or EGF (100 ng/ml, 5 min). 20 Wg of protein from the cell
lysate was run on a 4^12% polyacrylamide gel, transferred to nitro-
cellulose and immunoblotted with a phospho-GSK3K antibody.
Fig. 5. CREB and ATF1 phosphorylation in MSK13/3 cells.
CREB and ATF1 phosphorylation was examined in serum-starved
MSK13/3 and WT ES cells after stimulation with TPA (400 ng/
ml), EGF (100 ng/ml), or forskolin (20 WM) and IBMX (10 mM)
for the times indicated. In A, the cells were preincubated with 10
WM PD 184352 where indicated. Lysates were run on a 4^12% gra-
dient polyacrylamide gels, transferred to nitrocellulose and immuno-
blotted using antibodies that recognised Ser-133-phosphorylated
CREB and Ser-63-phosphorylated ATF1 or dephospho plus phos-
pho-CREB/ATF1 (total CREB). A: TPA- and EGF-induced phos-
phorylation of CREB and ATF1 in WT ES cells is mediated by the
classical MAPK cascade. B: Phosphorylation of CREB and ATF1
after TPA stimulation in WT and MSK13/3 ES cells. C: Phos-
phorylation of CREB and ATF1 after EGF stimulation of WT and
MSK13/3 ES cells. D: Phosphorylation of CREB and ATF1 after
forskolin (F) plus IBMX stimulation in WT and MSK13/3 ES
cells.
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K1 in WT ES cells. The phosphorylation of both proteins was
blocked by the MAPK cascade inhibitor PD 184352 (Fig. 5A).
In contrast, CREB and ATF1 phosphorylation induced by
either agonist was greatly reduced in MSK13/3 cells (Fig.
5B,C). This was not due to a decrease in the level of the
CREB and ATF1 proteins, which were similar in the WT
and MSK13/3 cells. Moreover, forskolin (an activator of
adenylate cyclase) and IBMX (an inhibitor of cAMP phos-
phodiesterases) induced a similar phosphorylation of CREB
and ATF1 in WT or MSK13/3 cells (Fig. 5D), indicating
that these proteins were still available for phosphorylation
by PKA.
4. Discussion
In this paper we show that, as in other cell types, mitogen-
induced CREB and ATF1 phosphorylation at Ser-133 and
Ser-63, respectively, is mediated via the classical MAPK path-
way. Importantly, we also show that the mitogen-induced
phosphorylation of these proteins is decreased in ES cells
that lack MSK1 (Fig. 5). This indicates that MSK1 is the
major protein kinase that mediates the TPA- and EGF-in-
duced phosphorylation and activation of these transcription
factors in ES cells. MSK1 is not acting indirectly by control-
ling the synthesis of MAPKAP-K1 isoforms, because the lev-
els of these protein kinases and their activation in response to
mitogens was similar in the MSK13/3 and WT ES cells (Fig.
4A^C). MAPKAP-K1 was also able to phosphorylate its sub-
strate GSK3K normally in MSK13/3 cells in response to
TPA or EGF (Fig. 4D). These observations, together with
the normal activation of ERK1/ERK2 in MSK13/3 cells
(Fig. 3B), indicates that the MSK1 ‘knockout’ does not ad-
versely a¡ect upstream MAPK signalling. We are currently
addressing whether the closely related MSK2 [8] or one or
more MAPKAP-K1 isoforms are responsible for the trace
residual TPA- and EGF-induced phosphorylation of CREB
in the MSK13/3 cells by the generation of an MSK13/3/
MSK23/3 double ‘knockout’.
The low level of phosphorylation of CREB and ATF1 seen
in unstimulated cells, which is una¡ected by inhibitors of the
classical MAPK cascade (data not shown) was similar in WT
and MSK13/3 cells, and must therefore be mediated by a
distinct protein kinase(s). This could be the basal activity of
PKA in unstimulated cells since forskolin and IBMX, which
elevate cAMP and activate PKA induced a much stronger
phosphorylation of CREB and ATF1 than EGF or TPA
(compare Fig. 5D with B,C). This is di¡erent from human
embryonic kidney ¢broblast 293 cells [8] and murine
RAW264.7 macrophages [18] that we have studied previously,
where activators of the classical MAPK cascade and forskolin
induce a similar degree of phosphorylation of CREB and
ATF1. This may be due to the low level of MSK1 in WT
ES cells, which is about 20-fold lower than in 293 cells or
RAW264.7 macrophages.
The present ¢ndings raise the question of why mitogens do
not apparently induce CREB/ATF1 phosphorylation in cells
from patients with Co⁄n^Lowry syndrome, which carry in-
activating mutations in the MAPKAP-K1b gene [10]. One
possible explanation is that MAPKAP-K1b is required for
the synthesis of MSK1, but this explanation is inconsistent
with the normal growth factor-induced activation of CREB
in the ¢broblasts of MAPKAP-K1b ‘knockout’ mice [11]. A
second possible explanation is that the inactive MAPKAP-
K1b in the Co⁄n^Lowry cells acts as a dominant negative
mutant binding to ERK1/ERK2 and thereby preventing them
from activating MSK1/MSK2. Although the MAPKAP-K1b
protein cannot be detected by immunoblotting of extracts
prepared from Co⁄n^Lowry cells [10], it is possible that pro-
teolytic fragments of MAPKAP-K1b are still present that
cannot be detected immunologically but which nevertheless
exhibit dominant negative e¡ects. A third possibility is that
Co⁄n^Lowry patients contain a second mutation that a¡ects
the synthesis or activity of MSK1. To our knowledge, the
level and activity of MSK1 and MSK2 has not yet been ex-
amined in Co⁄n^Lowry cells. This is clearly critical in order
to resolve this question.
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